The question showing up in GLP-1 communities is changing. It used to be, “How do I lose the weight?” Increasingly, it is, “I reached my goal—what happens now?”
Recent r/Semaglutide discussions ask how to define maintenance, whether treatment must continue and how to manage the cost after success. Another community account describes stopping because the medication was no longer affordable, followed by the return of cravings and some weight regain. In the public Mounjaro and Wegovy Weight Loss Support Group, members likewise describe cost-driven stops or switches, post-treatment regain and, in other cases, success supported by consistent exercise.
Those stories are anecdotes, not a controlled sample. They still expose the decision that clinical care now has to answer: a GLP-1 can help someone reach a healthier weight, but what preserves that success?
The direct answer: Maintenance is a treatment phase, not a finish line. For many people, the strongest evidence supports continued GLP-1 treatment in some form. Stopping commonly produces regain, while a new 2026 tirzepatide trial shows that a defined lower-dose strategy may preserve substantial benefit for some people. The long-term plan still has to account for health goals, access, tolerability, nutrition, strength and follow-up.
Maintenance does not have one universal definition
“Maintenance” can mean at least three different things:
- Weight stability: staying within a sustainable range rather than defending one exact scale reading.
- Health stability: preserving improvements in waist circumference, blood pressure, blood sugar, lipids, mobility or sleep even if weight moves modestly.
- A slower second phase: continuing gradual loss while the priority shifts toward strength, nutrition and a routine that can last.
Clinical trials do not use one shared maintenance threshold. Some measure average weight change after randomization. Others ask whether participants kept a specified percentage of their earlier loss. A personal plan may reasonably use several outcomes at once.
This matters because “goal weight” can create false precision. Day-to-day weight moves with water, food, glycogen and bowel contents. A small range is more realistic than a single number, and weight alone cannot show whether strength and metabolic health are holding up.
The community question has changed because the drugs worked
The shift toward maintenance is a sign of progress. Semaglutide and tirzepatide have moved peptide-based metabolic treatment from modest average weight loss to results that were difficult to reach with older options. The new problem is not whether these signals can work. It is how to preserve their benefit over years.
A June 2026 Reddit discussion asked whether people had maintained for two years or longer and raised the practical question of how long anyone can afford to continue. Replies included multi-year success stories and very different individual experiences. That is useful for identifying questions and possibilities. It cannot establish average outcomes, because people who post are self-selected and their treatment histories are not verified.
The trials supply the denominator that social media cannot.
What happens when semaglutide is stopped?
The best-known withdrawal evidence comes from the STEP program.
In the STEP 4 randomized withdrawal trial, participants first received semaglutide for 20 weeks and lost an average of 10.6% of body weight. Those who continued semaglutide for the next 48 weeks lost another 7.9%. Participants switched to placebo regained 6.9% over the same period. Waist circumference and systolic blood pressure also favored continued treatment.
The STEP 1 extension followed a smaller subset after both semaglutide and the trial’s lifestyle intervention ended. One year after withdrawal, participants had regained about two-thirds of their prior semaglutide-associated weight loss, and several cardiometabolic improvements moved back toward baseline.
The interpretation is not that every person will regain the same amount. These are group averages from structured trials. The consistent signal is that stopping removes an active biological effect. Returning hunger, reduced satiety and some regain are not evidence of weak character; they are predictable possibilities when the signal that supported the loss is removed.
Tirzepatide withdrawal produced the same broad pattern
In SURMOUNT-4, 670 adults who completed a 36-week tirzepatide lead-in were randomized either to continue treatment or switch to placebo. They had already lost an average of 20.9%.
From Week 36 through Week 88, continued treatment produced another 5.5% average loss. Switching to placebo produced 14.0% average regain. Nearly 90% of those who continued maintained at least 80% of their earlier loss, compared with 16.6% after withdrawal.
A later SURMOUNT-4 analysis connected greater regain after withdrawal with larger reversals in waist circumference, blood pressure, non-HDL cholesterol, hemoglobin A1c and fasting insulin. The maintenance decision is therefore about more than protecting a clothing size.
The 2026 trial makes maintenance more than “stay on or stop”
A June 2026 randomized trial, SURMOUNT-MAINTAIN, tested a question patients and clinicians have been asking for years. After a 60-week weight-loss phase on a maximum tolerated tirzepatide dose, participants were assigned to continue that dose, reduce to a defined 5 mg dose or switch to placebo for 52 weeks.
By Week 112, the estimated total weight change from the original baseline was −21.9% for participants who continued their maximum tolerated dose, −16.6% for the 5 mg group and −9.9% for placebo. Rescue tirzepatide was used by 8% of the continued-dose group, 25% of the 5 mg group and 67% of the placebo group among participants assessed under the study’s regain criteria.
This is a meaningful advance. It shows that a prospectively tested lower-dose arm can preserve a large share of average weight loss, while full-dose continuation preserved more. It also shows wide variation: some people in the lower-dose arm needed rescue treatment and many did not.
It does not validate improvised tapering, dose spacing or a universal “maintenance dose.” The study tested one defined tirzepatide dose under a protocol after a specific lead-in period. It was funded by Eli Lilly, the manufacturer. Independent replication, longer follow-up and direct comparisons of different maintenance strategies are still needed.
Current guidance treats obesity as a chronic condition
In December 2025, the World Health Organization issued a conditional recommendation for long-term liraglutide, semaglutide or tirzepatide treatment in adults with obesity, excluding pregnancy. WHO described obesity as a chronic, relapsing disease and paired medication with a conditional recommendation for intensive behavioral support that includes healthy eating and physical activity.
The word “conditional” is important. WHO cited remaining uncertainty about very long-term effectiveness and safety, what happens during maintenance and discontinuation, costs, equity and health-system readiness. That is not a rejection of GLP-1 treatment. It is a recognition that strong short- and medium-term efficacy has arrived faster than the evidence needed to design decades of care.
The FDA prescribing information for Wegovy likewise describes reducing excess body weight and maintaining weight reduction long term as part of the indication. Continued treatment is therefore the evidence-backed starting point for many patients, not a failure to become independent of medication.
Cost is changing treatment before science does
A long-term plan is not durable if the next refill is financially impossible. In a KFF national poll, about half of adults who had taken a GLP-1 said the cost was difficult to afford. Community reports of stopping, switching or stretching treatment because of price put a human face on that access gap.
This is not simply an adherence problem. A treatment can be clinically effective and economically unsustainable at the same time. Maintenance planning should address coverage, total monthly cost and continuity before a person is forced into an abrupt decision.
Lower-cost compounded or research-market peptides are part of the real-world landscape because the active molecules are not inherently mysterious and public demand does not disappear when coverage ends. Those pathways have different oversight, labeling, permitted claims and recourse. Regulatory category alone does not test a vial, and a lower price does not establish poor quality. Identity, amount, purity, endotoxin and sterility remain product- and lot-specific questions. Products labeled for research use are not a substitute for a patient-specific prescription or clinical follow-up.
Side effects can define the maintenance plan
The best maintenance strategy is not automatically the one that suppresses appetite most strongly. Nausea, vomiting, diarrhea, constipation, reflux, reduced intake and other adverse effects can change the benefit–risk balance. Gallbladder disease, pancreatitis concerns, dehydration and medication interactions may require closer evaluation.
Long-term review should include the exact product, other medications, symptoms, hydration, nutritional adequacy and relevant laboratory or clinical measures. That is especially important when diabetes medications are involved, because changes in intake, body weight and glucose control can alter the broader medication plan.
No withdrawal trial can tell an individual reader whether to continue, reduce, switch or stop. It can show what tended to happen under the study conditions and make the clinical conversation more informed.
Strength training changes what successful maintenance looks like
Weight maintenance is stronger when it protects physical capacity, not only a number on the scale.
A randomized trial follow-up offers one useful signal. Participants first lost weight with a low-calorie diet and then spent a year in an exercise program, liraglutide treatment, both or placebo. One year after the interventions ended, people originally assigned to supervised exercise—alone or combined with liraglutide—maintained weight and body composition better than those assigned to liraglutide alone.
That study used liraglutide and a structured exercise program; it does not prove that exercise will prevent regain after every GLP-1. It does support a practical principle: strength and fitness are active parts of maintenance, not cosmetic extras added after the “real” treatment is over.
Nutrition deserves the same status. Adequate protein and total energy, fiber-rich foods and a pattern that can be sustained help protect function and make appetite changes easier to interpret. A maintenance plan that produces a stable weight through chronic under-fueling is not a success.
A durable maintenance review tracks five domains
- Weight trajectory: a trend and a realistic range, not one daily reading.
- Metabolic health: waist circumference, blood pressure, glucose or A1c, lipids and other measures relevant to the individual.
- Strength and function: repeatable indicators such as resistance-training performance, walking capacity or daily physical tasks.
- Appetite and tolerability: hunger, satiety, food noise, gastrointestinal symptoms, hydration and nutritional intake.
- Access and follow-up: the ability to obtain the same verified product and keep regular clinical review without an unsustainable financial burden.
These domains make maintenance measurable. They also create a better trigger for reevaluation than waiting until a large regain has already occurred.
The unanswered questions are now more specific
Peptide science has already answered the first question: GLP-1-based treatments can produce clinically meaningful, durable weight loss while treatment continues. The next research agenda is more demanding:
- Who can maintain after discontinuation, and can that be predicted?
- What is the lowest effective long-term strategy for different patients?
- Does a structured reduction work better than abrupt withdrawal, and for whom?
- How should clinicians respond to returning hunger before substantial regain occurs?
- Which strength-training and nutrition programs best preserve lean tissue and function?
- How do outcomes change when cost, coverage and product continuity are treated as clinical variables?
SURMOUNT-MAINTAIN begins to answer one of those questions with randomized data. It should encourage more maintenance trials, not close the discussion.
Bottom line
Reaching a goal weight is not the end of GLP-1 treatment logic. It is the point where the goal changes.
The clearest evidence says that stopping semaglutide or tirzepatide commonly leads to regain, while continuing treatment preserves more of the benefit. New 2026 evidence adds a promising middle path: a defined lower tirzepatide dose preserved substantial average weight loss for many trial participants, though it did not perform as well as continued maximum tolerated treatment and did not work equally for everyone.
The practical lesson is to plan maintenance before cost, side effects or a final refill force the decision. Define the health target, protect strength and nutrition, secure a realistic access path and keep follow-up in place. GLP-1 peptides have changed what weight treatment can achieve. The next advance is learning how to make that success last.
Source record
- SURMOUNT-MAINTAIN randomized tirzepatide maintenance trial
- SURMOUNT-4 randomized tirzepatide withdrawal trial
- SURMOUNT-4 cardiometabolic analysis after withdrawal
- STEP 1 semaglutide withdrawal extension
- STEP 4 randomized semaglutide withdrawal trial
- Exercise and liraglutide follow-up after treatment termination
- WHO guideline on GLP-1 medicines for obesity
- FDA prescribing information for Wegovy
- KFF Health Tracking Poll on GLP-1 use and affordability
- r/Semaglutide long-term maintenance discussion identified in the trend review
- r/Semaglutide goal-weight maintenance discussion identified in the trend review
- r/Semaglutide post-treatment maintenance discussion identified in the trend review
- Mounjaro and Wegovy Weight Loss Support Group identified in the trend review
- Unsplash source photograph by Gilson Gomes
Research Pep News provides news and educational information, not individualized medical advice. GLP-1 medicines are prescription treatments with product-specific indications, contraindications and warnings. Do not change or stop a prescribed medication without the clinician responsible for the treatment. Products labeled for research use are not approved for human use.
This staff report was prepared for Research Pep News and is presented as news and educational information, not medical advice.
